Detalhe da pesquisa
1.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631003
2.
The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023.
Oncologist
; 29(2): 91-98, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048064
3.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407342
4.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
5.
Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists.
Int J Mol Sci
; 23(13)2022 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35806163
6.
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Cancer
; 127(13): 2204-2212, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33765337
7.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562145
8.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32673417
9.
A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.
Oncologist
; 25(2): 121-e213, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043778
10.
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Lancet Oncol
; 20(2): 297-310, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658932
11.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Lancet Oncol
; 20(4): 581-590, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30827746
12.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427204
13.
Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma.
Radiographics
; 39(4): 998-1016, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31199711
14.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 373(19): 1803-13, 2015 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26406148
15.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 373(19): 1814-23, 2015 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26406150
16.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.
J Transl Med
; 15(1): 205, 2017 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29020960
17.
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(7): 917-927, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27279544
18.
Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Oncologist
; 21(10): 1212-1217, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27382030
19.
Immunotherapy in kidney cancer: the past, present, and future.
Curr Opin Urol
; 26(6): 543-7, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27533501
20.
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
Prostate
; 75(14): 1518-25, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26012728